Clinical Trials on Gastrointestinal Carcinoma

Total 44158 results

BeiGene

Completed

A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma (ESCC)

Spain, United States, United Kingdom, China, Taiwan, Korea, Republic of, Japan, France, Germany, Belgium, Italy
National Health Research Institutes, Taiwan
China Medical University Hospital; Chang Gung Memorial Hospital; Kaohsiung Medical... and other collaborators

Enrolling by invitation

BI-754091 and Afatinib for Refractory Esophageal Squamous Cell Carcinoma (BEAR Study) (BEAR)

Esophageal Squamous Cell Carcinoma (ESCC)

Taiwan
Fudan University

Completed

A Study of SBRT for OligoMetastatic ESCC

Esophageal Squamous Cell Carcinoma Metastatic

China
Zhejiang University

Withdrawn

Nimotuzumab Plus Nab-paclitaxel and Cisplatin in Treating Patients With Advanced Esophageal Carcinoma

Stage IV Esophageal Squamous Cell Carcinoma

China
Genzyme, a Sanofi Company

Completed

Phase I FOLFOX Combination

Advanced Colorectal Carcinoma

Australia
Pfizer

Terminated

A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer

Metastatic Colorectal Carcinoma

United States, Canada, Spain
Cancer Institute and Hospital, Chinese Academy...
Akeso Pharmaceuticals, Inc.

Not yet recruiting

AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC

Metastatic Esophageal Squamous Cell Carcinoma | Unresectable Esophageal Squamous Cell Carcinoma | Locally Advanced Esophageal Squamous Cell Carcinoma
Shanghai Chest Hospital

Recruiting

Radiotherapy Combined With Immunochemotherapy in Metastatic Esophageal Squamous Cell Carcinoma

Esophageal Cancer | Esophageal Squamous Cell Carcinoma | Metastatic Esophageal Squamous Cell Carcinoma

China
Sun Yat-sen University
Jiangsu HengRui Medicine Co., Ltd.; Shanghai Junshi Bioscience Co., Ltd.

Recruiting

PD-1 Antibody Combined With mXELIRI Versus mXELIRI in the Second-line Setting for ESCC (Escape)

Esophageal Squamous Cell Carcinoma Abdominal Stage 0

China
Zhigang Li
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Trial Of Neoadjuvant Chemotherapy or Radiochemotherapy With Or Without SHR-1210 In Patients With Resectable ESCC.

Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

China
Fudan University
Shanxi Province Cancer Hospital; Jiangxi Provincial Cancer Hospital; Jiangsu... and other collaborators

Completed

A Comparison of Paclitaxel-based Three Regimens Concurrent With Radiotherapy for Patients With Local Advanced Esophageal Cancer

Stage III Esophageal Squamous Cell Carcinoma

China
National Taiwan University Hospital

Enrolling by invitation

The Ave-CRT Study for Newly Diagnosed Metastatic Esophageal Squamous Cell Carcinoma

Metastatic Esophageal Squamous Cell Carcinoma | Esophageal Tumor

Taiwan
National Taiwan University Hospital

Unknown

Neoadjuvant CCRT With/Without Bevacizumab for Locally Advanced ESCC

Stage III Esophageal Squamous Cell Carcinoma

Taiwan
Shandong University

Unknown

Early Detection of Head and Neck Superficial Squamous Cell Carcinoma in Patients With Esophagus Squamous Cell Carcinoma

Optical Enhancement Endoscopy

China
The First Affiliated Hospital of Henan University...
The First Affiliated Hospital of Zhengzhou University; No. 150 Central Hospital... and other collaborators

Unknown

The Role of Different Cycles of Chemotherapy（Capecitabine-oxaliplatin） in Esophageal Chemoradiotherapy (DCOECRT)

Esophageal Neoplasms | Stage III Esophageal Squamous Cell Carcinoma

China
Health Science Center of Xi'an Jiaotong University

Completed

Perioperative Vs. Preoperative Chemotherapy With Surgery in the Squamous Carcinoma of Esophagus

Squamous Carcinoma of Esophagus | Esophagus Disorders

China
Yuhong Li

Completed

FOLFIRI as Second Line Chemotherapy for Metastatic Esophageal Carcinoma

Advanced Esophageal Carcinoma

China
University of California, Irvine
Sanofi-Synthelabo

Terminated

Celecoxib/Oxaliplatin/Capecitabine for Gastric/Gastroesophageal Junction Carcinoma

Gastric Carcinoma | Gastroesophageal Junction Carcinoma

United States
Fudan University

Recruiting

TPF Concurrent Chemo-radiotherapy Plus Immunotherapy for Local Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Sixth Affiliated Hospital, Sun Yat-sen University

Recruiting

Radical Concurrent Chemoradiotherapy With DDP/5-FU and PD-1 Antibody for Non-metastatic Rectal Squamous Cell Carcinoma

Rectal Squamous Cell Carcinoma

China
West China Hospital

Recruiting

Neoadjuvant Adebrelimab With Dalpiciclib for Resectable Esophageal Squamous Cell Carcinomas

Esophageal Squamous Cell Carcinoma

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

Cadonilimab/Anlotinib in Locally Advanced or Relapsed/Metastatic ESCC Patients After Failure of PD-1 Combined With Platinum-containing Chemotherapy

Esophageal Squamous Cell Carcinoma

China
Peking Union Medical College Hospital

Recruiting

A Phase II Clinical Study of Fruquintinib Combined With S-1 for Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Fudan University

Recruiting

Peripheral Blood Neoantigen Specific T Cells Predict the Efficacy of Immunotherapy for Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Tao Jiang

Not yet recruiting

Envafolimab Combined With Chemotherapy in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital of Xinxiang Medical...
BeiGene

Not yet recruiting

Efficacy and Safety of Tislelizumab and Nab-paclitaxel Combined With Low-dose Radiotherapy in Patients With Stage IVb Esophageal Squamous Cell Carcinoma

ESCC
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Pembrolizumab Plus CRT Followed by Surgery in Upper ESCC

Esophageal Squamous Cell Carcinoma

China
Jiangxi Provincial Cancer Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients (ALTER-E005)

Digestive System Diseases | Gastrointestinal Diseases | Neoplasms by Histologic Type | Neoplasms by Site | Gastrointestinal Neoplasms | Digestive System Neoplasms | Carcinoma, Squamous Cell | Esophageal Neoplasms | Esophageal Diseases | Neoplasms, Squamous Cell | Esophageal Squamous Cell Carcinoma

China
Shanghai Zhongshan Hospital
Bristol-Myers Squibb

Recruiting

Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCC

Esophageal Squamous Cell Carcinoma

China
Sichuan Cancer Hospital and Research Institute

Recruiting

Selected Chemotherapy Combined Immunotherapy Treated High Risk Patient After NCRT in Resected Locally Advanced ESCC (ETNT)

Esophageal Squamous Cell Carcinoma

China
Fujian Cancer Hospital
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Subjects With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma (REVO)

Esophageal Neoplasms | Esophageal Squamous Cell Carcinoma

China
Tianjin Medical University Cancer Institute and...
Shanxi Province Cancer Hospital; Cancer Institute and Hospital, Chinese Academy... and other collaborators

Recruiting

Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002) (KEYSTONE-002)

Esophageal Squamous Cell Carcinoma

China
Wei Ren

Recruiting

Combination of Toripalimab and Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin and Capecitabine for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Hebei Medical University Fourth Hospital

Recruiting

Neoadjuvant Therapy With Nab-paclitaxel and Cisplatin for Locally Advanced Esophageal Squamous Cell Carcinoma (NTNC)

Esophageal Squamous Cell Carcinoma

China
Hebei Medical University Fourth Hospital

Not yet recruiting

A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma
Wangluowei

Active, not recruiting

Changhai Multimodal Esophageal Cancer Cohort (CMECC)

Esophageal Squamous Cell Carcinoma

China
Shanghai Zhongshan Hospital

Completed

Exploring the Optimal Timing of Minimally Invasive Surgery for Esophageal Squamous Cell Carcinoma

Time

China
Yonsei University

Completed

Preoperative Chemoradiotherapy and MK-3475 for Esophageal Squamous Cell Carcinoma (ACTS-29)

Esophageal Squamous Cell Carcinoma

Korea, Republic of
Qiu Guoqin

Enrolling by invitation

Neoadjuvant Chemoradiotherapy Followed by Sequential Immunotherapy for Thoracic Esophageal Squamous Cell Carcinoma (CRIS)

Esophageal Squamous Cell Carcinoma

China
Peking Union Medical College Hospital

Completed

Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Resectable Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Huai'an First People's Hospital
The Second People's Hospital of Huai'an; lian shui county People's Hospital; xuyi... and other collaborators

Completed

Postoperative Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Patients With Locoregionally Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Fudan University

Completed

Study of Extensive Clinical Target Volumes in Postoperative Radiotherapy Concurrent With Chemotherapy for Esophageal Squamous Cell Carcinoma (ESO-Shanghai9)

Esophageal Squamous Cell Carcinoma

China
Hecheng Li M.D., Ph.D

Completed

Preoperative Anti-PD-1 Antibody Combined With Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of Esophagus (PALACE-1)

Esophageal Squamous Cell Carcinoma

China
The First Affiliated Hospital with Nanjing Medical...

Enrolling by invitation

Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
First Affiliated Hospital Xi'an Jiaotong University

Active, not recruiting

Tislelizumab With Chemotherapy or Radiation for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma (TINES) (TINES)

Esophageal Squamous Cell Carcinoma

China
Shanghai Henlius Biotech

Active, not recruiting

A Clinical Trial Comparing HLX10 With Placebo Combined With Chemotherapy (Cisplatin + 5-fu) in the First-line Treatment of Locally Advanced/Metastatic Esophageal Squamous Cell Carcinoma (ESCC)

Esophageal Squamous Cell Carcinoma

China
Sun Yat-sen University

Completed

Percutaneous Endoscopic Gastrostomy Before Definitive Concurrent Chemoradiation Therapy for Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Withdrawn

S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCC

Esophageal Squamous Cell Carcinoma
Sun Yat-sen University

Completed

Moderately Hypofractionated Conformal Radiation Combined With S-1 for Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China

Clinical Trials on Gastrointestinal Carcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jamaica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations